The effect of deferasirox on endocrine complications in children with thalassemia

References

• De Sanctis V, Soliman AT, Elsedfy H, et al. Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocr Metab. 2013;17(1):8–18. doi:10.4103/2230-8210.107808.
   PubMedGoogle Scholar
• Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;21:5–11. doi:10.1186/1750-1172-5-11.
   Google Scholar
• Ouederni M, Ben Khaled M, Mellouli F, et al. Myocardial and liver iron overload, assessed using T2* magnetic resonance imaging with an excel spreadsheet for post processing in Tunisian thalassemia major patients. Ann Hematol. 2017;96(1):133–139. doi:10.1007/s00277-016-2841-5.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–1193.
   PubMed Web of Science ®Google Scholar
• Poggi M, Sorrentino F, Pugliese P, et al. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. Ann Hematol. 2016;95(5):757–763. doi:10.1007/s00277-016-2633-y.
   PubMed Web of Science ®Google Scholar
• Habeb AM, Al-Hawsawi ZM, Morsy MM, et al. Endocrinopathies in betathalassemia major. Prevalence, risk factors, and age at diagnosis in Northwest Saudi Arabia. Saudi Med J. 2013;34:67–73.
   PubMed Web of Science ®Google Scholar
• Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev. 2008;2008:158–169.
   Google Scholar
• Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta thalassemia major in North America. Blood. 2004;104(1):34–39. doi:10.1182/blood-2003-09-3167.
   PubMed Web of Science ®Google Scholar
• Telfer PT, Warburton F, Christou S, et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica. 2009;94(12):1777–1778. doi:10.3324/haematol.2009.009118.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin Ther. 2007;29(5):909–917. doi:10.1016/j.clinthera.2007.05.007.
   PubMed Web of Science ®Google Scholar
• Casale M, Citarella S, Filosa A, et al. Endocrine function and bone disease during longterm chelation therapy with deferasirox in patients with β-thalassemia major. Am J Hematol. 2014;89(12):1102–1106. doi:10.1002/ajh.23844.
   PubMed Web of Science ®Google Scholar
• Isik P, Yarali N, Tavil B, et al. Endocrinopathies in Turkish children with Beta thalassemia major: results from a single center study. Pediatr Hematol Oncol. 2014;31(7):607–615. doi:10.3109/08880018.2014.898724.
   PubMed Web of Science ®Google Scholar
• Capellini MD, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the Management of Transfusion Dependent Thalassemia (TDT). 3rd ed. TIF Publication NO. 20. Nicosia, Cyprus: Thalassemia International Federation; 2014.
   Google Scholar
• Neyzi O, Furman A, Bundak R, Bundak R, Gunoz H, Darendeliler F. Growth references for Turkish children aged 6 to 18 years. Acta Paediatr. 2006;95(12):1635–1641. doi:10.1080/08035250600652013.
   PubMed Web of Science ®Google Scholar
• Goksen D, Darcan S, Coker M, Kose T. Bone mineral density of healthy Turkish children and adolescents. J Clin Densitom. 2006;9(1):84–90. doi:10.1016/j.jocd.2005.08.001.
   PubMed Web of Science ®Google Scholar
• Saffari F, Mahyar A, Jalilolgadr S, Caspian J. Endocrine and metabolic disorders in β-thalassemiamajor patients. Caspian J Intern Med. 2012;3(3):466–472.
   PubMedGoogle Scholar
• Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood. 2009;114(19):4021–4026. doi:10.1182/blood-2009-06-225615.
   PubMed Web of Science ®Google Scholar
• Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT. Serum ferritin levels and endocrinopathy in medically treated patients with b thalassemia major. Ann Hematol. 2012;91(7):1107–1114. doi:10.1007/s00277-012-1412-7.
   PubMed Web of Science ®Google Scholar
• Taher A, El-Beshlawy A, Elalfy M, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassemia: the ESCALATOR Study. Eur J Haematol. 2009;82(6):458–465. doi:10.1111/j.1600-0609.2009.01228.x.
   PubMed Web of Science ®Google Scholar
• Nick H. Deferasirox (Exjade®, ICL670) preclinical overview. Semin Hematol. 2007;44(3):12–15.
   Google Scholar
• Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol. 2009;82(6):454–457. doi:10.1111/j.1600-0609.2008.01204.x.
   PubMed Web of Science ®Google Scholar
• Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalization of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466–475. doi:10.1111/j.1365-2141.2009.07970.x.
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. J Pediatr Endocrinol Metab. 2006;19(4):471–480.
   PubMed Web of Science ®Google Scholar
• Mohammadian S, Bazrafshan HR, Sadeghi-Nejad A. Endocrine gland abnormalities in thalassemia major: a brief review. J Pediatr Endocrinol Metab. 2003;16(7):957–964. doi:10.1515/jpem.2003.16.7.957.
   PubMed Web of Science ®Google Scholar
• Forni GL, Podesta M, Musso M, et al. Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with beta-thalassemia major. Haematologica. 2013;98(4):555–559. doi:10.3324/haematol.2012.076240.
   PubMed Web of Science ®Google Scholar
• Haidar R, Musallam KM, Taher AT. Bone disease and skeletal complications in patients with beta thalassemiamajor. Bone. 2011;48(3):425–432. doi:10.1016/j.bone.2010.10.173.
   PubMed Web of Science ®Google Scholar
• Tubman VN, Fung EB, Vogiatzi M, et al. Guidelines for the standard monitoring of patients with thalassemia: report of the thalassemia longitudinal cohort. J Pediatr Hematol Oncol. 2015;37(3):162–169.
   Web of Science ®Google Scholar
• Vogiatzi MG, for the Thalassemia Clinical Research Network, Macklin EA, Trachtenberg FL, Fung EB, Cheung AM, Vichinsky E, et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol. 2009;146(5):546–556. doi:10.1111/j.1365-2141.2009.07793.x.
   PubMed Web of Science ®Google Scholar